恒瑞医药注射用瑞康曲妥珠单纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received breakthrough therapy designation for its injectable SHR-A1811, marking the 10th indication for this drug [1] Group 1: Product Development - The injectable SHR-A1811 has been approved for domestic market launch in May 2025 [1] - It is indicated for adult patients with unresectable locally advanced or metastatic non-small cell lung cancer who have HER2 activating mutations and have previously received at least one systemic therapy [1]